# Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure

> **NCT02357615** · PHASE4 · UNKNOWN · sponsor: **Shanghai Shyndec Pharmaceutical Co., Ltd.** · enrollment: 244 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** nifedipine CR tablets (Xin Ran)
- **DRUG:** Adalat

## Key facts

- **NCT ID:** NCT02357615
- **Lead sponsor:** Shanghai Shyndec Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2015-06
- **Final completion:** 2015-09
- **Target enrollment:** 244 (ESTIMATED)
- **Last updated:** 2015-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02357615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02357615, "Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02357615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*